Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported;

MedShr· @medshronline · X·2026-10-24 23:15· 15 hours agoScore70

Body · original

Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported; full publication awaited.

#BreastCancer #Oncology #MedTwitter

63 views · 2 likes · 0 reposts · 0 replies

Conference abstracts

LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

Source: MedShr · x.com